Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937866 · ClinicalTrials.gov registry record · Phase 1
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
A Phase 1 study of Germ Cell Tumor, sponsored by Indiana University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT06937866: Recruiting Phase 1 study of Germ Cell Tumor, sponsored by Indiana University.
NCT06937866 is a Phase 1 study of Germ Cell Tumor that is actively recruiting participants, run by Indiana University. The registered enrollment target is 38 participants, below the 346-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06937866, a Phase 1 study of Germ Cell Tumor, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.
Primary Outcome
Rate of hematologic toxicity including neutropenia, anemia, or thrombocytopenia requiring intervention (transfusions or antibiotics)
Conditions Studied
Interventions
- DRUG Zanzalintinib
- DRUG Etoposide Capsule
Study Locations (1)
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2031-09 |
| Phase | Phase 1 |
What NCT06937866 shows while recruiting
NCT06937866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 346-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Germ Cell Tumor appearing as the primary indexed condition, and to 2 interventions - of which Zanzalintinib is the first listed.
NCT06937866 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06937866 about?
NCT06937866 is a clinical study titled "Maintenance Zanzalintinib With Etoposide After HDCT in GCT". This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.
What is the current status of trial NCT06937866?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2025-11-12. Estimated completion is 2031-09.
What conditions does trial NCT06937866 study?
This clinical trial studies the following conditions: Germ Cell Tumor.
What interventions are being tested in trial NCT06937866?
The interventions under investigation include: Zanzalintinib (DRUG), Etoposide Capsule (DRUG).
Who is sponsoring clinical trial NCT06937866?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937866 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06937866's enrollment target sits among peer trials
38 14th of 19 higher than 6 of 19 other Germ Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
ACTIVE NOT RECRUITING · Phase 1
-
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI